article thumbnail

STAT+: Life sciences deals on track to hit lowest point since 2017

STAT

If dealmaking remains consistent for the rest of the year, it would put this year on par with the number of deals made in 2017. For comparison, there were roughly 2,122 financing deals made last year. Continue to STAT+ to read the full story…

352
352
article thumbnail

Opinion: Want to keep schools safe? Hire more nurses

STAT

According to the New York Times, “Since 2017, tens of millions have been spent by the federal government on mass shooter training, and states have spent even more.” 

356
356
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system

STAT

billion in revenue by dispensing medicines to treat cancer, HIV, heart disease and other serious illnesses at prices that exceeded their estimated acquisition costs between 2017 and 2022. Specifically, the companies were able to generate more than $7.3 Continue to STAT+ to read the full story…

article thumbnail

STAT+: DOJ probes device maker whose test resulted in lucrative diagnoses for UnitedHealth and other insurers

STAT

The company indicated that the investigation began in 2017 and picked up in intensity in late 2024 and early 2025.    The SEC filing states that on Feb.   Continue to STAT+ to read the full story…

355
355
article thumbnail

STAT+: Device maker that helped UnitedHealth collect billions offers to settle fraud claims with DOJ

STAT

The DOJ began looking into the company in 2017, according to Semler, but re-upped its investigation in late 2024 and early 2025. The deal would cap an investigation Semler first disclosed in February into whether federal health programs paid out improper claims based on the use of QuantaFlo, which would violate the False Claims Act.

262
262
article thumbnail

STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail

STAT

Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse.

256
256
article thumbnail

STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds

STAT

In a brief statement , the Belgian Competition Authority alleged that Roche offered financial incentives to hospitals between 2017 and 2020 to deter them from considering competitive bids from other pharmaceutical companies that could supply similar medicines.